COMP <GO>
IMMX vs ABUS // EV/EBITDA & P/E VALUATION
Immix Biopharma Inc. (NASDAQ) VS. Arbutus Biopharma Corporation (NASDAQ) • 15-METRIC TALLY: IMMX 2
— ABUS 2
■ METRIC PARITY
LAST: $7.98 (-1.78%) • MKT CAP: $661.6M
valuation
—
LAST: $4.28 (-0.93%) • MKT CAP: $656.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMMX VS. ABUS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMMX | ABUS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.73% | -6.04% | +2.31 | IMMX | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 128.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.34 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ABUS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.3 | 39.9 | -9.61 | ABUS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $661.6M | $656.0M | $5.5M | IMMX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMMX REV | ABUS REV | IMMX GROSS % | ABUS GROSS % | IMMX FCF | ABUS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $14.1M | — | — | -$24.7M | -$39.6M |
| FY 2024 | $0 | $6.2M | — | — | -$15.8M | -$65.0M |
| FY 2023 | $0 | $18.1M | — | — | -$11.4M | -$85.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMMX // BETA —
ABUS // BETA —